Publications by authors named "Lloyd P Haskell"

Claim this Profile
R
Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.
Shea Hogan, Michael Szarek, E Sebastian Debus, Mark Nehler, Sonia S Anand, Lloyd P Haskell

J Am Heart Assoc· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Risk of Major Adverse Limb Events Following Lower Extremity Revascularization in the VOYAGER-PAD Trial.
R Kevin Rogers, Eike Sebastian Debus, Manesh R Patel, Sonia S Anand, Eva Muehlhofer, Lloyd P Haskell

JACC Cardiovasc Interv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization.
Mario Enrico Canonico, Cecilia C Low Wang, Judith Hsia, E Sebastian Debus, Mark R Nehler, Lloyd P Haskell

J Am Coll Cardiol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD.
Justin T Morrison, Mario Enrico Canonico, Sonia S Anand, Manesh R Patel, Eike Sebastian Debus, Lloyd P Haskell

Circulation· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methods, design, and initial results of an angiographic core lab from VOYAGER-PAD.
R Kevin Rogers, Joerg Herold, Nicholas Govsyeyev, Roberto Iezzi, Justin Morrison, Lloyd P Haskell

Vasc Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD.
Shea E Hogan, Eike Sebastian Debus, Mark R Nehler, Manesh R Patel, Sonia S Anand, Lloyd P Haskell

Circulation· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
Jennifer Rymer, Sonia S Anand, E Sebastian Debus, Lloyd P Haskell, Connie N Hess

Circulation· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Nicholas Govsyeyev, Mark Nehler, Michael S Conte, Sebastian Debus, Jayer Chung, Lloyd P Haskell

J Vasc Surg· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
Marc P Bonaca, Michael Szarek, E Sebastian Debus, Mark R Nehler, Manesh R Patel, Lloyd P Haskell

Clin Cardiol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Markus P Schlaich, Marc Bellet, Michael A Weber, Parisa Danaietash, George L Bakris, Lloyd P Haskell

Lancet· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD.
Shea E Hogan, Mark R Nehler, Sonia Anand, Manesh R Patel, Sebastian Debus, Lloyd P Haskell

Vasc Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD.
Connie N Hess, Iris Baumgartner, Sonia S Anand, Mark R Nehler, Manesh R Patel, Lloyd P Haskell

J Am Heart Assoc· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization.
Connie N Hess, Michael Szarek, Sonia S Anand, Rupert M Bauersachs, Manesh R Patel, Lloyd P Haskell

JAMA Netw Open· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Sonia S Anand, Will Hiatt, Leanne Dyal, Rupert Bauersachs, Scott D Berkowitz, Lloyd P Haskell

Eur J Prev Cardiol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone.
Scott D Berkowitz, Rupert M Bauersachs, Michael Szarek, Mark R Nehler, E Sebastian Debus, Lloyd P Haskell

J Thromb Haemost· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD.
Connie N Hess, E Sebastian Debus, Mark R Nehler, Sonia S Anand, Manesh R Patel, Lloyd P Haskell

Circulation· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD.
Connie N Hess, Manesh R Patel, Rupert M Bauersachs, Sonia S Anand, E Sebastian Debus, Lloyd P Haskell

J Am Coll Cardiol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
E Sebastian Debus, Mark R Nehler, Nicholas Govsyeyev, Rupert M Bauersachs, Sonia S Anand, Lloyd P Haskell

Circulation· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
Mori J Krantz, Sebastian E Debus, Judith Hsia, Manesh R Patel, Sonia S Anand, Lloyd P Haskell

Eur Heart J· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial.
Judith Hsia, Michael Szarek, Sonia Anand, Manesh R Patel, Sebastian Debus, Lloyd P Haskell

J Am Coll Cardiol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial.
Rupert M Bauersachs, Michael Szarek, Marianne Brodmann, Ivan Gudz, Eike Sebastian Debus, Lloyd P Haskell

J Am Coll Cardiol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban in Peripheral Artery Disease after Revascularization.
Marc P Bonaca, Rupert M Bauersachs, Sonia S Anand, E Sebastian Debus, Mark R Nehler, Lloyd P Haskell

N Engl J Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
Marc Pfister, Nancy E Martin, Lloyd P Haskell, Jeffrey S Barrett

J Clin Pharmacol· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis